î
îŒ
î
MeiraGTx Holdings PLC
MGTX7.970USD
-0.300-3.63%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
641.42Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± MeiraGTx Holdings PLC äŒæ¥å
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinsonâs disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Companyâs product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
MeiraGTx Holdings PLCã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãMGTX
äŒç€ŸåMeiraGTx Holdings PLC
äžå Žæ¥Jun 08, 2018
æé«çµå¶è²¬ä»»è
ãCEOãForbes (Alexandria)
åŸæ¥å¡æ°381
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 08
æ¬ç€Ÿæåšå°655 Third Avenue
éœåžNEW YORK
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·10017
é»è©±çªå·16468607985
ãŠã§ããµã€ãhttps://meiragtx.com/
äŒæ¥ã³ãŒãMGTX
äžå Žæ¥Jun 08, 2018
æé«çµå¶è²¬ä»»è
ãCEOãForbes (Alexandria)
MeiraGTx Holdings PLCã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
26.15K
-16.05%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sun, Nov 16
æŽæ°æå»: Sun, Nov 16
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Perceptive Advisors LLC
15.69%
Sanofi SA
15.15%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
ä»ã®
50.63%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Perceptive Advisors LLC
15.69%
Sanofi SA
15.15%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
ä»ã®
50.63%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
26.94%
Corporation
16.02%
Private Equity
15.69%
Venture Capital
8.29%
Investment Advisor
7.12%
Investment Advisor/Hedge Fund
4.38%
Individual Investor
4.17%
Research Firm
2.26%
Pension Fund
0.09%
ä»ã®
15.04%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Perceptive Advisors LLC
12.63M
15.69%
+45.00K
+0.36%
Jun 30, 2025
Sanofi SA
12.20M
15.16%
--
--
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.03M
7.5%
+400.00K
+7.10%
Jun 30, 2025
Prosight Capital
4.59M
5.7%
+895.88K
+24.27%
Jun 30, 2025
Rubric Capital Management LP
3.73M
4.63%
+1.95M
+109.78%
Jun 30, 2025
683 Capital Management LLC
2.69M
3.34%
+115.00K
+4.47%
Jun 30, 2025
Millennium Management LLC
785.18K
0.98%
+785.18K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.48M
3.09%
-243.04K
-8.91%
Jun 30, 2025
J. Goldman & Co., L.P.
2.04M
2.54%
+885.81K
+76.44%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Tue, Dec 2
æŽæ°æå»: Tue, Dec 2
éæå
æ¯ç
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Goldman Sachs Innovate Equity ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
詳现ãèŠã
iShares Micro-Cap ETF
æ¯ç0.07%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.07%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.07%
Goldman Sachs Innovate Equity ETF
æ¯ç0.06%
Vanguard US Momentum Factor ETF
æ¯ç0.04%
iShares Biotechnology ETF
æ¯ç0.04%
Invesco RAFI US 1500 Small-Mid ETF
æ¯ç0.02%
iShares Russell 2000 Growth ETF
æ¯ç0.02%
SPDR S&P International Small Cap ETF
æ¯ç0.02%
iShares Russell 2000 Value ETF
æ¯ç0.01%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
MeiraGTx Holdings PLCã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îMeiraGTx Holdings PLCã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Perceptive Advisors LLCã¯12.63Mæ ªãä¿æããŠãããããã¯å šäœã®15.69%ã«çžåœããŸãã
Sanofi SAã¯12.20Mæ ªãä¿æããŠãããããã¯å šäœã®15.16%ã«çžåœããŸãã
Johnson & Johnson Innovation-JJDC, Inc.ã¯6.64Mæ ªãä¿æããŠãããããã¯å šäœã®8.26%ã«çžåœããŸãã
Adage Capital Management, L.P.ã¯6.03Mæ ªãä¿æããŠãããããã¯å šäœã®7.50%ã«çžåœããŸãã
Prosight Capitalã¯4.59Mæ ªãä¿æããŠãããããã¯å šäœã®5.70%ã«çžåœããŸãã
Perceptive Advisors LLCã¯12.63Mæ ªãä¿æããŠãããããã¯å šäœã®15.69%ã«çžåœããŸãã
Sanofi SAã¯12.20Mæ ªãä¿æããŠãããããã¯å šäœã®15.16%ã«çžåœããŸãã
Johnson & Johnson Innovation-JJDC, Inc.ã¯6.64Mæ ªãä¿æããŠãããããã¯å šäœã®8.26%ã«çžåœããŸãã
Adage Capital Management, L.P.ã¯6.03Mæ ªãä¿æããŠãããããã¯å šäœã®7.50%ã«çžåœããŸãã
Prosight Capitalã¯4.59Mæ ªãä¿æããŠãããããã¯å šäœã®5.70%ã«çžåœããŸãã
MeiraGTx Holdings PLCã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îMeiraGTx Holdings PLCã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Perceptive Advisors LLC
Sanofi SA
Johnson & Johnson Innovation-JJDC, Inc.
Perceptive Advisors LLC
Sanofi SA
Johnson & Johnson Innovation-JJDC, Inc.
MeiraGTx Holdings PLCïŒMGTXïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãMeiraGTx Holdings PLCã®æ ªåŒãä¿æããŠããæ©é¢ã¯228瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ52.30Mã§ãå
šäœã®65.02%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-19.24%å¢å ããŠããŸãã
MeiraGTx Holdings PLCã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãMeiraGTx Holdings PLCã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
